Australië - Engels - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - tranexamic acid, quantity: 100 mg/ml - injection - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - adults for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery or total knee arthroplasty or total hip arthroplasty. paediatrics for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery.

Verenigde Staten - Engels - NLM (National Library of Medicine)

amring pharmaceuticals, inc. - tranexamic acid (unii: 6t84r30kc1) (tranexamic acid - unii:6t84r30kc1) - tranexamic acid 650 mg - tranexamic acid usp tablets are indicated for the treatment of cyclic heavy menstrual bleeding in females of reproductive potential [see clinical studies (14) ]. tranexamic acid usp tablets are contraindicated in females of reproductive potential who are [see warnings and precautions (5.1)]: - using combined hormonal contraception - known to have any of the following conditions: active thromboembolic disease (e.g., deep vein thrombosis, pulmonary embolism, or cerebral thrombosis) a history of thrombosis or thromboembolism, including retinal vein or artery occlusion an intrinsic risk of thrombosis or thromboembolism (e.g., thrombogenic valvular disease, thrombogenic cardiac rhythm disease, or hypercoagulopathy) - active thromboembolic disease (e.g., deep vein thrombosis, pulmonary embolism, or cerebral thrombosis) - a history of thrombosis or thromboembolism, including retinal vein or artery occlusion - an intrinsic risk of thrombosis or thromboembolism (e.g., thrombogenic valvul

Verenigde Staten - Engels - NLM (National Library of Medicine)

actavis pharma, inc. - tranexamic acid (unii: 6t84r30kc1) (tranexamic acid - unii:6t84r30kc1) - tranexamic acid 650 mg - tranexamic acid tablets are indicated for the treatment of cyclic heavy menstrual bleeding in females of reproductive potential [see clinical studies (14)] tranexamic acid tablets are contraindicated in females of reproductive potential who are [see warnings and precautions (5.1)] : - using combined hormonal contraception - known to have any of the following conditions: - active thromboembolic disease (e.g., deep vein thrombosis, pulmonary embolism, or cerebral thrombosis) - a history of thrombosis or thromboembolism, including retinal vein or artery occlusion - an intrinsic risk of thrombosis or thromboembolism (e.g., thrombogenic valvular disease, thrombogenic cardiac rhythm disease, or hypercoagulopathy) tranexamic acid tablets are contraindicated in females with reproductive potential with known hypersensitivity to tranexamic acid [see warnings and precautions (5.2) and adverse reactions (6.1)]. risk summary tranexamic acid tablets are not indicated for use in pregnant women. there are no available data

Verenigde Staten - Engels - NLM (National Library of Medicine)

apotex corp. - tranexamic acid (unii: 6t84r30kc1) (tranexamic acid - unii:6t84r30kc1) - tranexamic acid 650 - tranexamic acid tablets are indicated for the treatment of cyclic heavy menstrual bleeding in females of reproductive potential [see clinical studies (14) ]. tranexamic acid tablets are contraindicated in females of reproductive potential who are [see warnings and precautions (5.1)] - using combined hormonal contraception - known to have any of the following conditions: active thromboembolic disease (e.g., deep vein thrombosis, pulmonary embolism, or cerebral thrombosis) a history of thrombosis or thromboembolism, including retinal vein or artery occlusion an intrinsic risk of thrombosis or thromboembolism (e.g., thrombogenic valvular disease, thrombogenic cardiac rhythm disease, or hypercoagulopathy)   - active thromboembolic disease (e.g., deep vein thrombosis, pulmonary embolism, or cerebral thrombosis) active thromboembolic disease (e.g., deep vein thrombosis, pulmonary embolism, or cerebral thrombosis) - a history of thrombosis or thromboembolism, including retinal vein or artery occlusi

Verenigde Staten - Engels - NLM (National Library of Medicine)

prasco laboratories - tranexamic acid (unii: 6t84r30kc1) (tranexamic acid - unii:6t84r30kc1) - tranexamic acid 650 mg - tranexamic acid tablets are indicated for the treatment of cyclic heavy menstrual bleeding [see clinical studies (14) ]. prior to prescribing tranexamic acid tablets, exclude endometrial pathology that can be associated with heavy menstrual bleeding. do not prescribe tranexamic acid tablets to women who are - using combination hormonal contraception - known to have any of the following conditions: active thromboembolic disease (e.g., deep vein thrombosis, pulmonary embolism, or cerebral thrombosis) a history of thrombosis or thromboembolism, including retinal vein or artery occlusion an intrinsic risk of thrombosis or thromboembolism (e.g., thrombogenic valvular disease, thrombogenic cardiac rhythm disease, or hypercoagulopathy) - active thromboembolic disease (e.g., deep vein thrombosis, pulmonary embolism, or cerebral thrombosis) - a history of thrombosis or thromboembolism, including retinal vein or artery occlusion - an intrinsic risk of thrombosis or thromboembolism (e.g.,

Verenigde Staten - Engels - NLM (National Library of Medicine)

american health packaging - tranexamic acid (unii: 6t84r30kc1) (tranexamic acid - unii:6t84r30kc1) - tranexamic acid 650 mg - tranexamic acid tablets are indicated for the treatment of cyclic heavy menstrual bleeding [see clinical studies ( 14)]. prior to prescribing tranexamic acid tablets, exclude endometrial pathology that can be associated with heavy menstrual bleeding. do not prescribe tranexamic acid tablets to women who are - using combination hormonal contraception - known to have any of the following conditions: active thromboembolic disease (e.g., deep vein thrombosis, pulmonary embolism, or cerebral thrombosis) a history of thrombosis or thromboembolism, including retinal vein or artery occlusion an intrinsic risk of thrombosis or thromboembolism (e.g., thrombogenic valvular disease, thrombogenic cardiac rhythm disease, or hypercoagulopathy) - active thromboembolic disease (e.g., deep vein thrombosis, pulmonary embolism, or cerebral thrombosis) - a history of thrombosis or thromboembolism, including retinal vein or artery occlusion - an intrinsic risk of thrombosis or thrombo

Verenigde Staten - Engels - NLM (National Library of Medicine)

prasco laboratories - tranexamic acid (unii: 6t84r30kc1) (tranexamic acid - unii:6t84r30kc1) - tranexamic acid 650 mg - tranexamic acid tablets are indicated for the treatment of cyclic heavy menstrual bleeding [see clinical studies (14) ]. prior to prescribing tranexamic acid tablets, exclude endometrial pathology that can be associated with heavy menstrual bleeding. do not prescribe tranexamic acid tablets to women who are known to have the following conditions: - active thromboembolic disease (e.g., deep vein thrombosis, pulmonary embolism, or cerebral thrombosis) - a history of thrombosis or thromboembolism, including retinal vein or artery occlusion - an intrinsic risk of thrombosis or thromboembolism (e.g., thrombogenic valvular disease, thrombogenic cardiac rhythm disease, or hypercoagulopathy) venous and arterial thrombosis or thromboembolism, as well as cases of retinal artery and retinal vein occlusions, have been reported with tranexamic acid. do not prescribe tranexamic acid tablets to women with known hypersensitivity to tranexamic acid [see warnings and precautions (5.2) and adverse reactions (6.1) ]. tranexamic

Australië - Engels - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - tryptophan, quantity: 1.9 g/l; arginine, quantity: 11.3 g/l; phenylalanine, quantity: 7.9 g/l; cysteine, quantity: 0.56 g/l; tyrosine, quantity: 0.23 g/l; glycine, quantity: 7.9 g/l; threonine, quantity: 5.6 g/l; methionine, quantity: 5.6 g/l; leucine, quantity: 7.9 g/l; alanine, quantity: 16 g/l; isoleucine, quantity: 5.6 g/l; aspartic acid, quantity: 3.4 g/l; lysine acetate, quantity: 12.7 g/l (equivalent: lysine, qty 9 g/l); serine, quantity: 4.5 g/l; histidine, quantity: 6.8 g/l; proline, quantity: 6.8 - injection, intravenous infusion - excipient ingredients: glacial acetic acid; water for injections - intravenous supply of amino acids specially to patients with highly increased requirement who are unable to receive sufficient amounts of protein enterally. vamin 18 is also indicated where there is a need to control the total amount of fluid being given to a patient.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - cysteine, quantity: 0.42 g/l; leucine, quantity: 5.9 g/l; tryptophan, quantity: 1.4 g/l; isoleucine, quantity: 4.2 g/l; alanine, quantity: 12 g/l; tyrosine, quantity: 0.17 g/l; histidine, quantity: 5.1 g/l; serine, quantity: 3.4 g/l; lysine acetate, quantity: 9.5 g/l (equivalent: lysine, qty 6.8 g/l); aspartic acid, quantity: 2.5 g/l; valine, quantity: 5.5 g/l; phenylalanine, quantity: 5.9 g/l; glycine, quantity: 5.9 g/l; methionine, quantity: 4.2 g/l; arginine, quantity: 8.4 g/l; threonine, quantity: 4.2 g - injection, intravenous infusion - excipient ingredients: water for injections; glacial acetic acid - intravenous supply of amino acids to patients with moderately increased requirement who are unable to receive sufficient amounts of protein enterally

Australië - Engels - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - leucine, quantity: 4.02 g/l; phenylalanine, quantity: 3.08 g/l; methionine, quantity: 2.2 g/l; lysine hydrochloride, quantity: 3.99 g/l (equivalent: lysine, qty 3.19 g/l); isoleucine, quantity: 3.3 g/l; valine, quantity: 3.19 g/l; histidine, quantity: 2.64 g/l; threonine, quantity: 2.31 g/l; tryptophan, quantity: 990 mg/l; alanine, quantity: 11.4 g/l; glycine, quantity: 5.66 g/l; arginine, quantity: 6.32 g/l; proline, quantity: 3.74 g/l; tyrosine, quantity: 220 mg/l; serine, quantity: 2.75 g/l; sodium aceta - injection, intravenous infusion - excipient ingredients: sodium metabisulfite; glacial acetic acid; water for injections - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)